The return on investment in health care: From 1980 to 2000

被引:53
作者
Luce, BR
Mauskopf, J
Sloan, FA
Ostermann, J
Paramore, LC
机构
[1] United BioSource Corp, Bethesda, MD 20814 USA
[2] RTI Int, Durham, NC USA
[3] Duke Univ, Durham, NC USA
关键词
health policy; innovation; Medicare claims; return on investment;
D O I
10.1111/j.1524-4733.2006.00095.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To estimate the return on US investment (ROI) in overall health as well as four specific conditions. Methods: The study utilized three distinct approaches to "triangulate" the evidence as related to ROI in health care: 1) an estimation of the average ROI in additional health-care service expenditures in the United States for the year 2000 compared with the year 1980, based on US summaries of health expenditures and health outcomes; 2) an estimate of the ROI in Medicare services for the period from 1985 to 2000 for treatment of heart attack, stroke, type 2 diabetes, and breast cancer, based on National Long-term Care Survey data and Medicare claims; and 3) an estimate of the ROI for selected major treatment innovations for the same four conditions during the period from 1975 to 2000. Results: We calculated that each additional dollar spent on overall health-care services produced health gains valued at $1.55 to $1.94 under our base case assumptions. The return on health gains associated with treatment for heart attack, stroke, type 2 diabetes, and breast cancer were $1.10, $1.49, $1.55, and $4.80, respectively, for every additional dollar spent by Medicare. The ROI for specific treatment innovations ranged from both savings in treatment costs and gains in health to gains in health valued at $1.12 to $38.00 for every additional dollar spent. Conclusion: The value of improved health in the US population in 2000 compared with 1980 significantly outweighs the additional health-care expenditures in 2000 compared with 1980.
引用
收藏
页码:146 / 156
页数:11
相关论文
共 47 条
[11]  
CUTLER DM, 2001, HEALTH AFFAIR, V20, P11
[12]   SHOULD THE ELDERLY RECEIVE CHEMOTHERAPY FOR NODE-NEGATIVE BREAST-CANCER - A COST-EFFECTIVENESS ANALYSIS EXAMINING TOTAL AND ACTIVE LIFE-EXPECTANCY OUTCOMES [J].
DESCH, CE ;
HILLNER, BE ;
SMITH, TJ ;
RETCHIN, SM .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :777-782
[13]   Model of Complications of NIDDM .2. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia [J].
Eastman, RC ;
Javitt, JC ;
Herman, WH ;
Dasbach, EJ ;
CopleyMerriman, C ;
Maier, W ;
Dong, F ;
Manninen, D ;
Zbrozek, AS ;
Kotsanos, J ;
Garfield, SA ;
Harris, M .
DIABETES CARE, 1997, 20 (05) :735-744
[14]   Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients [J].
Elliott, WJ ;
Weir, DR ;
Black, HR .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (09) :1277-1283
[15]   Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke [J].
Fagan, SC ;
Morgenstern, LB ;
Petitta, A ;
Ward, RE ;
Tilley, BC ;
Marler, JR ;
Levine, SR ;
Broderick, JP ;
Kwiatkowski, TG ;
Frankel, M ;
Brott, TG ;
Walker, MD .
NEUROLOGY, 1998, 50 (04) :883-890
[16]  
GERDTHAM UG, 2000, HDB HLTH EC A, V1, pCH1
[17]  
GERDTHAM UG, 2000, HDB HLTH EC B, V1
[18]   The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors [J].
Golan, L ;
Birkmeyer, JD ;
Welch, HG .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (09) :660-+
[19]   COSTS AND EFFECTIVENESS OF ROUTINE THERAPY WITH LONG-TERM BETA-ADRENERGIC ANTAGONISTS AFTER ACUTE MYOCARDIAL-INFARCTION [J].
GOLDMAN, L ;
SIA, STB ;
COOK, EF ;
RUTHERFORD, JD ;
WEINSTEIN, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (03) :152-157
[20]   How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? [J].
Grover, SA ;
Coupal, L ;
Zowall, H ;
Alexander, CM ;
Weiss, TW ;
Gomes, DRJ .
DIABETES CARE, 2001, 24 (01) :45-50